Core Laboratories NV (CLB)

Core Laboratories NV has shown consistent liquidity strength based on its liquidity ratios for the four quarters in 2024. Firstly, the current ratio, which measures the company's ability to cover its short-term obligations with its current assets, averaged around 2.47 throughout the year, indicating that the company had more than enough current assets to cover its current liabilities.

Secondly, the quick ratio, a more stringent measure of liquidity that excludes inventory from current assets, hovered around 1.58 on average, showing that Core Laboratories NV could meet its short-term obligations even without relying on selling inventory.

Lastly, the cash ratio, which is the most conservative liquidity ratio that only considers cash and cash equivalents to cover current liabilities, averaged around 0.20 for the year, indicating that the company had a modest amount of cash reserves relative to its current liabilities.

Overall, Core Laboratories NV's liquidity ratios suggest that the company maintained a solid liquidity position throughout 2024, with a healthy ability to meet its short-term obligations using various levels of current assets.

---

Additional liquidity measure

The cash conversion cycle of Core Laboratories NV has shown a decreasing trend throughout the year 2024. Starting at 3,875.85 days in March, it decreased to 3,364.87 days by June, further reducing to 3,249.49 days by September, and ultimately reaching a significantly lower level of 108.96 days by the end of December. This trend indicates an improvement in the company's ability to convert its resources effectively into cash during the year, with the December figure suggesting a much more efficient cash conversion process.